Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medications for acid-related ailments and various oncological conditions. This company was established on May 7, 2020, and maintains its principal office in Seoul, South Korea.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalued on EV/EB
Target Price
The average target price of 476060.KQ is 12500 and suggests 15.9% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendatio